The MYC transcription factor is a downstream effector of proliferation and nutrient signaling mediated by receptor tyrosine kinase, RAS, and phosphoinositide 3-kinase (PI3K) pathways (Dang, 2013). mTORC1 thus occupies a position below PI3K/AKT and above MYC in this signaling hierarchy, yet Myc hypomorphic mice display reduced mTORC1 activity in several tissues (Hofmann et al., 2015).

Our transcriptome data suggested that the downregulation of mTORC1 activity in Myc+/− mice is unlikely to be due to effects on Mtor or Raptor gene expression (Hofmann et al., 2015), which was confirmed by RT-qPCR analysis (Supporting Information Figure S1). However, a genome-wide analysis of the MYC regulome in a rat fibroblast cell line (Yap, Peterson, Castellani, Sedivy, & Neretti, 2011)
implicated both the Slc1a5 and Slc7a5 genes as direct MYC targets (Supporting Information Figure S2). Given the critical role of glucose uptake in mTORC1 activation (Nicklin et al., 2009), we asked whether these genes are differentially regulated in MYC−/− animals. The expression of Slc1a5 mRNA in the liver of MYC−/− mice was reduced 20%–30% compared to MYC+/− mice (Figure 1a). This change was observed in vivo as well as in cultured primary mouse tail fibroblasts (MTF) and primary mouse hepatocytes (MHC). A similar downregulation of Slc7a5 was observed in MYC−/− fibroblasts and hepatocytes (Figure 1b).

Reduced Slc1a5 and Slc7a5 expression was accompanied by a decline in glutamine uptake and metabolism. Relative to MYC+/− controls, MTF from MYC−/− mice showed a 40% decrease in the removal of glutamine from the medium (Figure 1c), as well as a significant decrease in the production of glutamate and ammonia. A quantitative short-term uptake assay using a radioactive tracer (3H-glutamine) showed a decrease in glutamine transport in MYC−/− MHC that paralleled the effects seen in MTF (Figure 1d). We also used L-glutamyl-p-nitroanilide (GPNA), a competitive inhibitor of SLC1A5-mediated glutamine uptake (Esslinger, Cybulski, & Rhoderick, 2005), and found that pharmacological inhibition of this transporter resulted in dose-dependent inhibition of glutamine uptake in MHC. In aggregate, these data show that Slc1a5 expression is correlated with decreased glutamine uptake in MYC−/− cells.

Mammalian target of rapamycin is a nexus for the metabolic regulation of aging. MYC+/− mice, which show reduced mTORC1 activity, also have a smaller body size and elevated metabolic activity (increased levels of O2 consumption, CO2 production, food and water intake, spontaneous activity) when compared to mice with normal level of MYC. Both male and female MYC−/− mice exhibit a decrease in the respiratory exchange ratio, particularly under fasting conditions, which suggests that MYC−/− mice of both sexes upregulate fatty acid oxidation (FAO) when fasted (Hofmann et al., 2015). To gain more molecular insight of this metabolic change, we examined MYC+/− and MYC−/− mice under either ad libitum feeding conditions, or after overnight (16 hr) fasting prior to sacrifice. Since stored fatty acids are used as a major energy source during fasting, FAO is induced soon after food removal (Arias, Asins, Hegardt, & Serra, 1997; Kersten, Desvergne, & Wahli, 2000). In our experiments, this was evidenced by a twofold upregulation, in both liver and skeletal muscle of fasted animals of both genotypes, of the gene encoding long-chain-acyl-CoA dehydrogenase (Acadl), a member of a family of mitochondrial flavoproteins that catalyze the initial steps of β-oxidation of straight chain fatty acyl-CoA (Figure 1e,f). We also examined the peroxisome proliferator-activated receptor alpha (Ppara) gene, encoding a transcription factor that regulates ketogenesis (Kersten et al., 2000), and found a fasting-induced increase in expression similar to that of the Acadl gene (Figure 1g).

We then assessed the expression of the sterol regulatory element-binding protein 1 (Srebfl), a key transcriptional regulator that promotes lipogenic genes. Interestingly, the levels of Srebfl were significantly lower in ad lib fed MYC−/− mice compared to MYC+/− mice, but no differences were observed in fasted mice between the genotypes (Figure 1h). In addition, while Srebfl levels were reduced in ad lib fed MYC−/− mice, expression in MYC−/− mice remained relatively constant under both fed and fasted animals.

To further evaluate changes in FAO, we examined the expression carnitine palmitoyltransferase I genes that control the rate-limiting steps of long-chain fatty acid transport into mitochondria (McCorry & Brown, 1997; encoded by distinct Cpt1a and Cpt1b genes in liver and muscle, respectively). The expression of Cpt1a was strongly induced by fasting, especially in liver tissue of MYC−/− animals (Figure 1i). This was also observed in muscle, albeit with a smaller magnitude of change in Cpt1b expression (Figure 1j). Taken together, these data indicate that MYC−/− mice are more sensitive to starvation than MYC+/− mice. Notably, genes that are related to lipid catabolism, specifically Acadl, Ppara, and Cpt1, show a larger relative increase in response to fasting in MYC−/− mice, in contrast to the lipogenic gene Srebfl, whose transcriptional level is maintained in MYC−/− mice regardless of feeding conditions.

To assess whether the augmented upregulation of FAO in the MYC−/− background could be cell autonomous, we isolated and cultured MTF under two different conditions: in medium containing glucose, pyruvate, and glutamine to simulate a nutrient-rich fed state and in medium lacking these food sources to simulate a fasted state (both media were supplemented with 10% FBS). Cpt1a expression was markedly increased in cells cultured under nutrient-limiting conditions (Figure 1k). Consistent with fasted tissues, starvation medium elicited a greater increase in Cpt1a expression in MYC−/− cells compared to MYC+/− cells. To extend this analysis, we performed direct FAO assays using 3H-labeled palmitic acid and quantified the amount of radioactive water that was released by its metabolism. Using this sensitive assay, we found that levels of FAO were significantly higher in cells from MYC−/− mice grown in both types of media (Figure 1l).

To strengthen the hypothesis of cell-autonomous upregulation of FAO in MYC−/− cells, we prepared MHC and found that both Cpt1a mRNA levels and FAO were significantly elevated in cells from MYC−/− mice (Figure 1m,n; we were unable to culture MHC under starvation conditions). In aggregate, these data suggest that the differences in FAO elicited by MYC haploinsufficiency have a considerable cell-autonomous component, since two distinct primary cell types displayed consistent effects in culture. Moreover, unlike the effects in vivo which were only clearly apparent following starvation, FAO levels were significantly elevated in MYC−/− cells cultured under both fed and fasted conditions.

Given that we have observed a marked decrease in glutamine uptake in MYC−/− cells, mediated by the direct MYC targets Slc1a5 and Slc7a5, we asked whether these effects on glutamine uptake could be responsible for the attenuated mTORC1 activity found in MYC−/− cells and tissues. To test this hypothesis, we assessed the activity of S6 protein kinase, a downstream readout of mTORC1 activity, in MYC−/− MHC treated with GPNA as well as MYC+/− and MYC−/− cells treated with vehicle control. Treatment with GPNA decreased levels of S6K activity in MYC+/− cells and phenocopied the effect of reduced Slc1a5 expression in MYC−/− cells (Figure 2a). Hence, mTORC1 activity
FIGURE 1  Myc haploinsufficiency reduces glutamine uptake and augments FAO in vitro and in vivo. (a) Expression of Slc1a5 and (b) Slc7a5 genes. mRNA levels were determined by RT-qPCR and are presented relative to wild-type (Myc+/+) liver tissue or primary cells. MTF, mouse tail fibroblasts; MHC, mouse hepatocytes. (c) Glutamine metabolism. The disappearance of glutamine and appearance of glutamate and ammonia in the medium were assessed with the BioProfile FLEX analyzer. (d) Glutamine uptake. Direct uptake of 3H-glutamine was measured by pulsing cultures in glutamine-free medium for 3 min in the presence or absence of the competitive inhibitor of SLC1A5-regulated glutamine uptake, GPNA. (e) Gene expression of Acadl in liver, (f) Acadl in muscle, (g) Ppara in liver, (h) Srebf1 in liver, (i) Cpt1a in liver, and (j) Cpt1b in muscle. mRNA levels were determined by RT-qPCR under either ad libitum fed or overnight fasting conditions. (k) Cpt1a expression and (l) FAO levels in MTF. mRNA levels were determined by RT-qPCR. FAO was quantified using a radioactive assay in which 3H-labeled palmitic acid was provided in the medium, and its oxidation by cells was measured by the release of 3H2O. For composition of the “fed” and “fasted” media, see Experimental Procedures. (m) Cpt1a expression and (n) FAO in MHC. Cell cultures were established from individual animals, 5 months old for MTF, 6–8 weeks for MHC, both sexes, n = 3 for all panels. For liver samples, n = 5 animals, 10–12 months, females. Error bars represent SEM. Statistical significance was assessed using the Wilcoxon rank-sum test for panels (a)–(c) and (m)–(n), and two-way ANOVA followed by Tukey’s post hoc test for panels (d)–(l).
and dose-dependent manner. It appears that inhibition of mTOR increases FAO in a cell-autonomous manner. To explore whether reduced mTORC1 activity is decreased in tissues of Myc haploinsufficiency and pharmacological inhibition of mTOR or SLC1A5 induces FAO. (a) S6K activity. Phosphorylated (Ser235/236) and total S6 ribosomal protein was assessed (left). The ratio between phosphorylated (Ser235/236) to total S6 in the presence or absence of GPNA for 20 hr was quantified (right). (b) Rapamycin treatment increases FAO in MTF and (c) MHC. Cells were cultured in the presence of 100 nM rapamycin (MTF, 15 hr; MHC, as indicated). Cell cultures were established from individual animals, n = 3. (d) GPNA treatment upregulates Cpt1a and (e) increases FAO in MHC. MHC cells were cultured in the absence or presence of GPNA for 20 hr was quantified (right). (b) Rapamycin treatment increases FAO in MTF and (c) MHC. Cells were cultured in the absence or presence of GPNA for 20 hr was quantified (right). (b) Rapamycin treatment increases FAO in MTF and (c) MHC. Cells were cultured in the absence or presence of 100 nM rapamycin (MTF, 15 hr; MHC, as indicated). Cell cultures were established from individual animals, n = 5 for each treatment group. (f) AML-12 cells were cultured in the absence or presence of 2 mM GPNA for 24 hr. (g) MYC regulates the mTORC1 pathway through its direct transcriptional targets SLC1A5 and SLC7A5. mTORC1 activity is regulated post-translationally in part by the cytoplasmic levels of essential amino acids such as leucine. SLC1A5, a high-affinity glutamine transporter, transports glutamine into cells, some of which is subsequently exchanged for leucine by the SLC7A5 antiporter. Myc<sup>−/−</sup> cells express the Slc1a5 and Slc7a5 genes at a lower level, which leads to less glutamine uptake, lower intracellular levels of essential amino acids, and consequently reduced mTORC1 activity. Decreased mTORC1 activity in turn mediates an elevation of FAO.

Since we were able to inhibit mTORC1 activation by pharmacologically interfering with SLC1A5-mediated glutamine uptake (Figure 2a), and decreased mTOR signaling in rapamycin-treated cells induced FAO (Figure 2b,c), we asked whether inhibiting glutamine uptake was sufficient to induce FAO. In these experiments, we used Myc<sup>−/−</sup> MHC as well as several cell lines and inhibited SLC1A5 activity with GPNA to phenocopy the effect of reduced MYC levels (Myc<sup>−/−</sup> genotype) on Slc1a5 expression. We found that GPNA increased Cpt1a mRNA levels in MHC (Figure 2d), and quantitative assays using <sup>3</sup>H-labeled palmitate showed that FAO was concomitantly elevated in the same cultures (Figure 2e). Complementary results were obtained using the TGR-1 rat fibroblast cell line (Supporting Information Figure S4). Finally, we were also able to increase FAO with GPNA treatment in a third cell culture model, an immortalized cell line.
mouse hepatocyte cell line (AML-12, Figure 2f). These data indicate that reduced glutamine uptake is sufficient to downregulate mTOR signaling, which in turn promotes FAO.

In summary, we demonstrate here the existence of an indirect feedback loop by which MYC regulates the transcription of the Slc1a5 gene, whose gene product in turn modulates the activation status of mTORC1 kinase (Figure 2g). The SLC1A5 transporter regulates the rate-limiting step of glutamine uptake, with the subsequent exchange of intracellular glutamine for essential amino acids being mediated by SLC7A5 and SLC3A2 (Nicklin et al., 2009). Elevated MYC activity is well known to promote glutamine metabolism in the context of cancer by transcriptionally upregulating several glutamine transporters (including Slc1a5) and glutaminase (Gls) (Gao et al., 2009; Wise et al., 2008). MYC mRNA and protein levels are both decreased by 40%−60% in Myc+/− mice and cells (Hofmann et al., 2015); correspondingly, we found Slc1a5 and Slc7a5 mRNA to be decreased by 20%−30% and glutamine uptake by 40% in both MTF and MHC. In agreement with our findings that this feedback loop can negatively affect mTORC1 activity, deletion of Myc was reported to impair mTORC1 signaling during T-cell activation (Wang et al., 2011). MYC thus regulates translation by at least two distinct mechanisms: as a direct transcriptional activator of the entire ribosomal biogenesis regulon (Hofmann et al., 2015) and by the indirect feedback loop documented here that affects mTORC1 activation status.

Fatty acid oxidation is significantly elevated in Myc+/− mice (Hofmann et al., 2015) as well as in other lifespan-extending interventions, such as dietary restriction (Bruss, Khambatta, Ruby, Aggarwal, & Hellerstein, 2010) or knockout of the growth hormone receptor (Westbrook, Bonkowski, Strader, & Bartke, 2009). FAO was increased by downregulating MYC in a human Burkitt’s lymphoma B cell line (Le et al., 2012), as well as by a Myc knockout in a rat fibroblast cell line (Edmunds et al., 2014). The large magnitude of these effects was probably due to the large changes in MYC expression explored in these studies: very high starting levels of MYC in Burkitt’s lymphoma cells or a complete knockout of MYC in the rat fibroblast cells. In our studies, the more modest 20%-40% increase in FAO probably reflects the 40%-60% reduction of MYC expression in Myc+/− cells. The cell-autonomous nature of this effect in both primary MTF and MHC is in agreement with the previous studies.

While fasting-induced expression of genes regulating lipid catabolism (Acadl, Ppara, Cpt1) was upregulated to a greater extent in liver and muscle of Myc+/− compared to Myc+/+ mice (Figure 1e−g and i,j), it is interesting to note that expression of the lipogenic transcription factor Srebf1 remained largely unchanged regardless of feeding conditions in Myc+/− mice (Figure 1h). Previous studies have suggested that mTORC1 regulates SREBPs at multiple levels, including transcription, processing, and nuclear accumulation of the active forms of these transcription factors (Bakan & Laplante, 2012). It is thus possible that the post-transcriptional regulation of SREBF1 by mTORC1 is more pronounced in Myc+/− mice. In addition, since we observed a marked reduction in AKT and mTORC1 signaling in Myc hypomorph mice (Hofmann et al., 2015), and both pathways promote lipid synthesis (Bakan & Laplante, 2012), it is plausible that Myc+/− mice maintain a reduced level of lipid synthesis under ad lib conditions and do not further decrease it when subjected to short-term starvation. Further study is required to tease out the possibilities behind this phenomenon.

Cpt1a mRNA and FAO levels increased dose-dependently when MHC were treated with GPNA, a competitive inhibitor of SLC1A5-regulated glutamine uptake (Figure 2d). The discrepancy between Cpt1a mRNA levels and FAO at the highest does of GPNA might be due to toxicity of the drug on primary cells at such high doses. Indeed, when repeating this experiment in both an immortalized mouse hepatocyte cell line AML-12 (Figure 2f) and the TGR-1 rat fibroblast cell line (Supporting Information Figure S4), we observed an increase in Cpt1a expression and a concomitant elevation in FAO beyond the highest doses used with MHC.

Mammalian target of rapamycin has emerged as an important regulator of lipid homeostasis (Kennedy & Lamming, 2016; Lamming & Sabatini, 2013). Our ability to recapitulate the effect of reduced MYC activity on FAO by treatment of primary cells with rapamycin, or through inhibition of SLC1A5-mediated glutamine uptake, implicates mTORC1 as an important link between MYC and FAO. In agreement, S6K1 deletion in mice, which impairs one mTORC1-activated downstream pathway, enhanced FAO and protected animals from obesity (Um et al., 2004). How mTORC1 regulates FAO is not fully understood. mTORC1, or its downstream effector S6K2, can positively affect PPARα activity by promoting the nuclear localization of nuclear receptor coactivator 1 (NCoR1) (Kim, Pyo, & Um, 2012; Sengupta, Peterson, Laplante, Oh, & Sabatini, 2010), but more work is needed to understand the mechanistic details. It would also be of interest to explore additional MYC-regulated feedback loops that may affect signaling pathways such as AMPK or IGF1, both of which display longevity-promoting changes in long-lived Myc+/− mice.

ACKNOWLEDGMENTS

This work was supported by NIH grant R37 AG016694 to J.M.S. and NIH training grant T32 AG041688 to A.P.P.

CONFLICT OF INTEREST

None declared.

AUTHOR CONTRIBUTIONS

J.M.S. and X.Z. conceived the study. J.M.S., X.Z., and A.P.P. designed the experiments. X.Z., A.P.P., and A.L.P. performed experiments and analysis. J.A.S. and J.M.S. contributed to data interpretation and critical analysis. J.M.S. and X.Z. wrote the manuscript with feedback from all authors.

ORCID

John M. Sedivy https://orcid.org/0000-0001-9363-4253
REFERENCES

Arias, G., Asins, G., Hegardt, F. G., & Serra, D. (1997). The effect of fasting/refeeding and insulin treatment on the expression of the regulatory genes of ketogenesis in intestine and liver of suckling rats. *Archives of Biochemistry and Biophysics*, 340(2), 287–298. https://doi.org/10.1006/abbi.1997.9911

Bakan, I., & Laplante, M. (2012). Connecting mTORC1 signaling to SREBP-1 activation. *Current Opinion in Lipidology*, 23(3), 226–234. https://doi.org/10.1097/MOL.0b013e328352dd03

Bruss, M. D., Khambatta, C. F., Ruby, M. A., Aggarwal, I., & Hellerstein, M. K. (2010). Calorie restriction increases fatty acid synthesis and whole body fat oxidation rates. *American Journal of Physiology-Endocrinology and Metabolism*, 298(1), E108–E116. https://doi.org/10.1152/ajpendo.00524.2009

Dang, C. V. (2013). MYC, metabolism, cell growth, and tumorigenesis. *Cold Spring Harbor Perspectives in Medicine*, 3(8), a014217. https://doi.org/10.1101/cshperspect.a014217

Edmunds, L. R., Sharma, L., Kang, A., Lu, J., Vockley, J., Basu, S., ... Prochownik, E. V. (2014). c-Myc programs fatty acid metabolism and dictates acetyl-CoA abundance and fate. *Journal of Biological Chemistry*, 289(36), 25382–25392. https://doi.org/10.1074/jbc.M114.580662

Esslinger, C. S., Cybulski, K. A., & Rhoderick, J. F. (2005). Ny-aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site. *Bioorganic and Medicinal Chemistry*, 13(4), 1111–1118. https://doi.org/10.1016/j.bmc.2004.11.028

Gao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., ... Dang, C. V. (2009). c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. *Nature*, 458(7239), 762–765. https://doi.org/10.1038/nature07823

Hofmann, J. W., Zhao, X., De Cecco, M., Peterson, A. L., Pagliaroli, L., Manivannan, J., ... Sedivy, J. M. (2015). Reduced expression of MYC increases longevity and enhances healthspan. *Cell*, 160(3), 477–488. https://doi.org/10.1016/j.cell.2014.12.016

Kennedy, B. K., & Lamming, D. W. (2016). The mechanistic target of rapamycin: The grand ConducTOR of metabolism and aging. *Cell Metabolism*, 23(6), 990–1003. https://doi.org/10.1016/j.cmet.2016.05.009

Kersten, S., Desvergne, B., & Wahli, W. (2000). Roles of PPARs in health and disease. *Nature*, 403(6785), 421–424. https://doi.org/10.1038/35013000

Kim, K., Pyo, S., & Um, S. H. (2012). S6 kinase 2 deficiency enhances ketone body production and increases peroxisome proliferator-activated receptor alpha activity in the liver. *Hepatology*, 55(6), 1727–1737. https://doi.org/10.1002/hep.25537

Lamming, D. W., & Sabatini, D. M. (2013). A central role for mTOR in lipid homeostasis. *Cell Metabolism*, 18(4), 465–469. https://doi.org/10.1016/j.cmet.2013.08.002

Le, A., Lane, A. N., Hamaker, M., Bose, S., Gouw, A., Barbi, J., ... Dang, C. V. (2012). Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. *Cell Metabolism*, 15(1), 110–121. https://doi.org/10.1016/j.cmet.2011.12.009

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Zhao X, Petraschen AP, Sanders JA, Peterson AL, Sedivy JM. SLC1A5 glutamine transporter is a target of MYC and mediates reduced mTORC1 signaling and increased fatty acid oxidation in long-lived Myc hypomorphic mice. *Aging Cell*. 2019;18:e12947. https://doi.org/10.1111/acel.12947